U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H23NO
Molecular Weight 221.3385
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAPENTADOL

SMILES

CC[C@H]([C@@H](C)CN(C)C)C1=CC=CC(O)=C1

InChI

InChIKey=KWTWDQCKEHXFFR-SMDDNHRTSA-N
InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21476608 | https://www.nucynta.com/hcp/er/mechanism-of-action#isi-0

Tapentadol is the first US FDA-approved centrally acting analgesic having both μ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition. Tapentadol is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.16 µM [Ki]
8.8 µM [Ki]
5.28 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NUCYNTA

Approved Use

NUCYNTA ER (tapentadol) is indicated for the management of: pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
221.34 ng/mL
86 mg single, oral
dose: 86 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAPENTADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
221.34 ng × h/mL
86 mg single, oral
dose: 86 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAPENTADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.16 h
86 mg single, oral
dose: 86 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAPENTADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAPENTADOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAPENTADOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes.
2008 Jan
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
2009 Feb
A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain.
2009 Mar
[Tapentadol. Opioid analgesic and norepinephrine reuptake inhibitors].
2010 Dec
Stereochemical basis for a unified structure activity theory of aromatic and heterocyclic rings in selected opioids and opioid peptides.
2010 Feb 18
Tapentadol immediate release: a new treatment option for acute pain management.
2010 Feb 8
In vitro and in vivo characterization of tapentadol metabolites.
2010 Jan-Feb
Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
2010 Jul
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain.
2010 Jun
Tapentadol immediate-release for acute pain.
2010 Jun
Recent advances in postoperative pain management.
2010 Mar
Determination of tapentadol and its metabolite N-desmethyltapentadol in urine and oral fluid using liquid chromatography with tandem mass spectral detection.
2010 Oct
Determination of tapentadol (Nucynta®) and N-desmethyltapentadol in authentic urine specimens by ultra-performance liquid chromatography-tandem mass spectrometry.
2010 Oct
Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain.
2010 Sep
Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
2013 Apr
Tapentadol hydrochloride: A novel analgesic.
2013 Jul
Patents

Sample Use Guides

As with many centrally-acting analgesic medications, the dosing regimen of NUCYNTA® should be individualized according to the severity of pain being treated, the previous experience with similar drugs and the ability to monitor the patient. Initiate NUCYNTA® with or without food at a dose of 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability. Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are, therefore, not recommended.
Route of Administration: Oral
Upon exposure to tramadol and tapentadol concentrations up to 600μM, cell toxicity was assessed through evaluation of oxidative stress, mitochondrial and metabolic alterations, as well as cell viability and death mechanisms through necrosis or apoptosis, and related signalling. Tapentadol was observed to trigger much more prominent toxic effects than tramadol, ultimately leading to energy deficit and cell death.
Name Type Language
TAPENTADOL
DASH   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BN-200
Preferred Name English
TAPENTADOL [USAN]
Common Name English
3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol
Systematic Name English
tapentadol [INN]
Common Name English
TAPENTADOL [VANDF]
Common Name English
NSC-759619
Code English
PHENOL, 3-((1R,2R)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL)-
Systematic Name English
CG-5503
Code English
CG5503 IR
Code English
TAPENTADOL [MI]
Common Name English
TAPENTADOL [MART.]
Common Name English
Tapentadol [WHO-DD]
Common Name English
CG5503
Code English
Classification Tree Code System Code
NDF-RT N0000175690
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
NCI_THESAURUS C241
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
WHO-VATC QN02AX06
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
WHO-ATC N02AX06
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
LIVERTOX 923
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
DEA NO. 9780
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
NDF-RT N0000000174
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
Code System Code Type Description
IUPHAR
7477
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
HSDB
8309
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
NCI_THESAURUS
C72139
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
EPA CompTox
DTXSID30170003
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
NSC
759619
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
DRUG BANK
DB06204
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
MERCK INDEX
m10459
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY Merck Index
PUBCHEM
9838022
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
DRUG CENTRAL
4283
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
CAS
175591-23-8
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
LACTMED
Tapentadol
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
DAILYMED
H8A007M585
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
WIKIPEDIA
TAPENTADOL
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
FDA UNII
H8A007M585
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
USAN
QQ-108
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
EVMPD
SUB31821
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
MESH
C523979
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
INN
8216
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
SMS_ID
100000124502
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201776
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY
RXCUI
787390
Created by admin on Mon Mar 31 18:28:21 GMT 2025 , Edited by admin on Mon Mar 31 18:28:21 GMT 2025
PRIMARY RxNorm